UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________ FORM 10-Q ____________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number 001-36407 ____________________ ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2020 Earnings Conference Call May 5, 2020 10:00 AM ET Company Participants Christine Lindenboom - VP, IR and Corporate Communications John Maraganore - CEO Barry Greene - President Akshay Vaishnaw - President of R&D Jeff Poulton - Chief Financial Officer Yvonne Greenstreet - Chief Operating Officer Conference Call Participants David Lebowitz - Morgan Stanley Tazeen Ahmad - Bank of America Paul Matteis - Stifel Anupam Rama - JP Morgan Ritu Baral - Cowen Salveen ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________ FORM 10-Q ____________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number 001-36407 ___________________ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________________________ Form 10-K _____________________________________________________________________________________________ ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2019 Earnings Conference Call February 6, 2020 8:30 AM ET Company Participants Christine Lindenboom - Vice President-Investor Relations and Corporate Communications John Maraganore - Chief Executive Officer Barry Greene - President Pushkal Garg - Chief Medical Officer Jeff Poulton - Chief Financial Officer Yvonne Greenstreet - Chief Operating Officer Conference Call Participants Emma Nealon - Cantor Fitzgerald & Co. Salveen Richter - Goldman Sachs David Lebowit ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________ FORM 10-Q ____________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number 001-36407 _______________ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number 001-36407 ALNYLAM PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) | --- | --- | --- | --- | ...